ANI Pharmaceuticals, Inc.
NASDAQ:ANIP · NASDAQ Global Market
-$1.42 today
Vol 0.32M · Avg 0.35M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $78.3M +522.9% | -$18.5M -198.6% | $18.8M +139.2% | -$47.9M -12.4% | -$42.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $91.4M +35.0% | $67.7M +13.3% | $59.8M +0.2% | $59.7M +26.2% | $47.3M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $14.2M +165.0% | -$21.9M -86.7% | -$11.7M +23.0% | -$15.3M +9.0% | -$16.8M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $37.9M +29.3% | $29.3M +42.1% | $20.7M +41.5% | $14.6M +39.2% | $10.5M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$7.1M +36.3% | -$11.2M -145.0% | $24.9M +148.5% | -$51.3M -60971.4% | -$84.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$58.5M -177.6% | -$21.1M -727.8% | $3.4M +109.1% | -$36.9M -565.3% | -$5.5M | $592.6M | $1.3B | $626.2M |
| Inventory | -$6.0M +72.0% | -$21.3M -264.4% | -$5.8M +75.3% | -$23.6M -832.8% | $3.2M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $15.2M +3064.1% | $479.0K -93.7% | $7.6M +49.9% | $5.0M -50.4% | $10.2M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $42.2M +37.5% | $30.7M +55.2% | $19.8M +371.2% | $4.2M +153.0% | -$7.9M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$29.6M -259.3% | $18.6M +180.5% | $6.6M -26.4% | $9.0M +79.1% | $5.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $185.2M +189.3% | $64.0M -46.2% | $119.0M +481.2% | -$31.2M -1039.3% | $3.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$34.3M -102.4% | -$17.0M +8.4% | -$18.5M -12.5% | -$16.5M +30.4% | -$23.6M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 +100.0% | -$401.3M | $0 +100.0% | -$33.0K +100.0% | -$84.5M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$20.5M -260.1% | $12.8M +232.7% | -$9.6M -41.2% | -$6.8M +63.0% | -$18.4M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$34.3M +91.5% | -$404.7M -2086.4% | -$18.5M -17.6% | -$15.7M +85.1% | -$105.5M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$10.2M -102.9% | $345.2M +11607.3% | -$3.0M +0.0% | -$3.0M -103.0% | $99.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $13.6M | $0 -100.0% | $80.6M | $0 -100.0% | $69.6M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$12.2M -11.4% | -$11.0M -119.8% | -$5.0M -154.6% | -$2.0M -120.1% | -$890.0K | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$1.2M +28.8% | -$1.6M +0.0% | -$1.6M +0.0% | -$1.6M -755.3% | -$190.0K | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$26.0K +100.0% | -$67.7M -1831.8% | -$3.5M -340.3% | $1.5M -29.5% | $2.1M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$9.9M -103.8% | $264.9M +292.9% | $67.4M +1415.6% | -$5.1M -102.6% | $194.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$233.0K +50.4% | -$470.0K | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $140.7M +284.6% | -$76.2M -145.4% | $167.9M +422.4% | -$52.1M -156.3% | $92.4M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $150.9M +220.6% | $47.1M -53.1% | $100.4M +310.8% | -$47.7M -134.6% | -$20.3M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Hisamitsu Pharmaceutical Co., Inc.
HTSUF
$2.04B
Dermapharm Holding SE
DMPHF
$1.96B
Fagron N.V.
ARSUF
$1.95B
Trulieve Cannabis Corp.
TCNNF
$1.82B
Green Thumb Industries Inc.
GTBIF
$1.74B
Tsumura & Co.
TSMRF
$1.73B
Harrow Health, Inc.
NASDAQ:HROW
$1.57B
CanSino Biologics Inc.
CASBF
$999.02M
Tilray Brands, Inc.
NASDAQ:TLRY
$560.26M
BGM Group Ltd.
NASDAQ:BGM
$79.13M
SEC Filings
Recent regulatory filings
No filings found.
Does ANIP generate free cash flow?
ANI Pharmaceuticals, Inc. (ANIP) generated $150.90M of free cash flow in fiscal 2025.
How much operating cash flow does ANIP produce?
Operating cash flow was $185.22M, before capital expenditures of $34.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.